Quantum Computing Inc vs Smith & Nephew plc — how do they compare? Quantum Computing Inc trades at $8.03 (market cap $1.86B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc is far larger — about 6.3× Quantum Computing Inc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| QUBT | SNN | |
|---|---|---|
Market Cap | $1.86B | $11.63B |
Sector | Technology | Health |
52-Week High | $24.62 | $38.53 |
52-Week Low | $6.31 | $27.80 |
Enterprise Value | $927.53M | $14.66B |
Dividend Yield | — | 2.85% |
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $8.22, up 2.62% today, amid bearish technical signals and challenging fundamentals. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, with negative profit margins across all metrics. However, analyst sentiment remains optimistic with a 75% buy rating and $19 consensus price target, supported by recent government funding announcements and institutional investments from BlackRock and Bank of New York Mellon.
QUBT offers speculative growth potential in quantum computing but carries significant execution risks. The stock's 131% upside to analyst targets contrasts with persistent losses and high cash burn. Investors face volatility from unproven technology commercialization while banking on long-term quantum adoption. Key catalysts include contract wins and manufacturing scale-up, but profitability remains years away.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →